CV Date	24/01/2023

Part A. PERSONAL INFORMATION

First Name	Juan Carlos		
Family Name	Rodríguez Manzaneque Escribano		
Sex	Male	Date of Birth	
ID number Social Security, Passport			
URL Web	http://www.genyo.es/en/content/grupo?id=20111013416912119932711446223		
Email Address	juancarlos.rodriguez@genyo.es		
Open Researcher and Contributor ID (ORCID)	0000-0001-5951-7029		

A.1. Current position

Job Title	Principal Investigator		
Starting date	2008		
Institution	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD		
Department / Centre	Oncología Genómica / GENYO. Centro de Genómica e Investigación Oncológica: Pfizer/Universidad de Granada/Junta de Andalucía		
Country		Phone Number	
Keywords	Biomedicine; Cell biology		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2007 - 2008	Group Leader (Contrato Ramón y Cajal) / FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON
2002 - 2007	Group Leader (Contrato FIS) / FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON
1998 - 2002	Postdoctoral Researcher / University of California Los Angeles
1997 - 1998	Postdoctoral Researcher / Beth Israel Deaconess Medical Center / Harvard Medical School / United States of America
1991 - 1996	Graduate Student / DEP. BIOQUÍMICA Y BIOLOGÍA MOLECULAR, FACULTAD DE MEDICINA, UNIVERSIDAD COMPLUTENSE DE MADRID

A.3. Education

Degree/Master/PhD	University / Country	Year
Bioquímica y Biología Molecular, Facultad de Farmacia	Universidad Complutense de Madrid	1996
Licenciado en Farmacia	Universidad Complutense de Madrid	1991

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

1 **Scientific paper**. Sanchez-Martin V; Plaza-Calonge MC; Soriano-Lerma A; et al; García-Salcedo JA. 2022. Gallic Acid: A Natural Phenolic Compound Exerting Antitumoral Activities in Colorectal Cancer via Interaction with G-Quadruplexes Cancers. 14-11, pp.2648. https://doi.org/10.3390/cancers14112648

2 **Scientific paper**. Lopez-Millan B; Costales P; Gutierrez-Agüera F; et al; Menendez P. 2022. The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Cancers. 14-6, pp.1593. https://doi.org/10.3390/cancers14061593

3 **Scientific paper**. Díaz de la Guardia R; Velasco-Hernandez T; Gutierrez-Agüera F; et al; Menendez P. 2021. Engraftment characterization of risk-stratified AML patients in NSGS mice Blood Advances. https://doi.org/10.1182/bloodadvances.2020003958

4 **Scientific paper**. de Assis Lima M; Vieira da Silva S; Serrano-Garrido O; Hülsemann M; Santos-Neres L; Rodríguez-Manzaneque JC; Hodgson L; Freitas VM. 2021. Metalloprotease ADAMTS-1 decreases cell migration and invasion modulating the spatiotemporal dynamics of Cdc42 activity Cellular Signalling. 77, pp.109827. ISSN 0898-6568.

5 **Scientific paper**. Serrano-Garrido, O; Peris-Torres, C; Redondo-García, S; Asenjo, HG; Plaza-Calonge, MC; Fernandez-Luna, JL; Rodríguez-Manzaneque, JC. 2020. ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression Biomolecules. 11-1, pp.44. https://doi.org/10.3390/biom11010044

6 **Scientific paper**. Redondo-García, S; Peris-Torres, C; Caracuel-Peramos, R; Rodríguez-Manzaneque, JC. 2020. ADAMTS proteases and the tumor immune microenvironment: Lessons from substrates and pathologies Matrix Biology Plus. 9. https://doi.org/10.1016/j.mbplus.2020.100054

7 **Scientific paper**. Carrillo-Gálvez AB; Quintero JE; Rodríguez R; et al; Anderson P. 2020. GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β Cell Death Dis. 11-985. ISSN 2041-4889.

8 **Scientific paper**. Peris-Torres, C; Plaza-Calonge, MC; López-Domínguez, R; Domínguez-García, S; Barrientos-Durán, A; Carmona-Sáez, P; Rodríguez-Manzaneque, JC. 2020. Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells Cancers (Basel). 12-4, pp.801. ISSN 2072-6694. https://doi.org/10.3390/cancers12040801

9 **Scientific paper**. Rodríguez-Baena, FJ; Redondo-García, S; Peris-Torres, C; Martino-Echarri, E; Fernández-Rodríguez, R; Plaza-Calonge, MC; Anderson, P; Rodríguez-Manzaneque, JC. 2018. ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response Scientific Reports. 8-1, pp.13103. ISSN 2045-2322. https://doi.org/10.1038/s41598-018-31288-7

10 **Scientific paper**. Prieto, C; López-Millán, B; Roca-Ho, H; et al; Menendez-Buján, Pablo. 2018. NG2 Antigen is involved in Leukemia Invasiveness and Central Nervous System Infiltration in MLL-rearranged Infant B-ALL Leukemia. 32-3, pp.633-644. ISSN 0887-6924. https://doi.org/10.1038/leu.2017.294

11 **Scientific paper**. Fernández-Rodríguez R; Rodríguez-Baena FJ; Martino-Echarri E; Peris-Torres C; Plaza-Calonge MC; Rodríguez-Manzaneque JC. 2016. Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis Oncotarget. 7-23, pp.34507-34519. ISSN 1949-2553.

12 **Scientific paper**. Santos-Oliveira P; Correia A; Rodrigues T; et al; Travasso RD. 2015. The Force at the Tip - Modelling Tension and Proliferation in Sprouting Angiogenesis.PLoS Computational Biology. 11-8, pp.e1004436.

13 **Scientific paper**. Rodríguez-Manzaneque, JC; Fernández-Rodríguez, R; Rodríguez-Baena, FJ; Iruela-Arispe, ML. 2015. ADAMTS proteases in vascular biology Matrix Biology. 44-46, pp.38-45.

14 **Scientific paper**. Martino-Echarri E; Fernández-Rodríguez R; Bech-Serra JJ; et al; Rodríguez-Manzaneque JC. 2014. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1 Oncotarget. 5-12, pp.4295-4304. ISSN 1949-2553.

15 **Scientific paper**. Martino-Echarri, Estefanía; Fernández-Rodríguez, R; Rodríguez-Baena, FJ; et al; Rodríguez-manzaneque, Juan Carlos. (1.111/). 2013. Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2 International Journal of Cancer. 133-10, pp.2315-2324. ISSN 1097-0215.

16 **Scientific paper**. Bueno-Uroz, Clara; Montes-Lorenzo, Rosa Mª; Ramos-Mejía, Veronica; et al; Menendez-Buján, Pablo. (1.415/). 2012. A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification.CELL RESEARCH. 22-6, pp.986-1002.

17 **Scientific paper**. Travasso, R.D.; Corvera Poiré, E.; Castro, M.; Rodríguez-Manzaneque, J.C.; Hernández-Machado, A.(45/). 2011. Tumor angiogenesis and vascular patterning: a mathematical model.PLOS ONE. 6-5, pp.e19989.

18 **Scientific paper**. Casal-Moreno, Carmen; Torres-Collado-, Ax; Plaza-Calonge-, Maria Del Carmen; Martino-Echarri, Estefanía; Ramón Y Cajal-Agüeras,Santiago; Rojo-, F.; Griffioen-,A.W.; Rodríguez-manzaneque, Juan Carlos. (88/). 2010. ADAMTS1 CONTRIBUTES TO THE ACQUISITION OF AN ENDOTHELIAL-LIKE PHENOTYPE IN PLASTIC TUMOR CELLS.Cancer Research. 70-11, pp.4676-4686.

19 **Scientific paper**. Reynolds-,L.E.; Watson-,Alan R.; Baker-,Marianne; et al; Hodivala-Dilke-,Kairbaan M.(923/). 2010. TUMOUR ANGIOGENESIS IS REDUCED IN THE TC1 MOUSE MODEL OF DOWN'S SYNDROME Nature (London). 465-7299, pp.813-817.

20 **Scientific paper**. Rodríguez-Manzaneque-Escribano, Juan Carlos; Carpizo-,D; Plaza-Calonge-,Mc; et al; Iruela-Arispe-,Ml. (18/). 2009. CLEAVAGE OF SYNDECAN-4 BY ADAMTS1 PROVOKES DEFECTS IN ADHESION.International journal of biochemistry & cell biology. 41-4, pp.800-810.

21 **Scientific paper**. Torres-Collado-, Ax; Kisiel-,W; Iruela-Arispe-,Ml; Rodríguez-Manzaneque-Escribano, Juan Carlos. 2006. ADAMTS1 INTERACTS WITH, CLEAVES, AND MODIFIES THE EXTRACELLULAR LOCATION OF THE MATRIX INHIBITOR TISSUE FACTOR PATHWAY INHIBITOR-2.The Journal of biological chemistry (Print). 281-26, pp.17827-17837.

22 **Scientific paper**. Canals, F; Colomé,N; Ferrer,C; Plaza-Calonge, MC; Rodríguez-Manzaneque, J.C.2006. IDENTIFICATION OF SUBSTRATES OF THE EXTRACELLULAR PROTEASE ADAMTS1 BY DIGE PROTEOMIC ANALYSIS.Proteomics (Weinheim. Print). 6-SUPP, pp.S28-S35.

23 **Scientific paper**. Rodríguez-manzaneque, Juan Carlos; Lane-,Tf; Ortega-,M.A.; Hynes-,Ro; Lawler-,J; Iruela-Arispe-,Ml. 2001. THROMBOSPONDIN-1 SUPPRESSES SPONTANEOUS TUMOR GROWTH AND INHIBITS ACTIVATION OF MATRIX METALLOPROTEINASE-9 AND MOBILIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR.Proceedings of the National Academy of Sciences of the United States of America. 98-22, pp.12485-12490.

24 **Book chapter**. Peris Torres, C.; Serrano, O.; Plaza Calonge, MDC.; Rodríguez Manzaneque, JC.2020. Inhibition of ADAMTS1 Expression by Lentiviral CRISPR/Cas9 Gene Editing Technology.Methods in molecular biology (Clifton, N.J.). 2043, pp.13-24. ISSN 1940-6029.

25 **Book chapter**. Rodríguez-Baena FJ; Redondo-García S; Plaza-Calonge MC; Fernández-Rodríguez R; Rodríguez-Manzaneque JC. 2018. Evaluation of tumor vasculature using a syngeneic tumor model in wild type and genetically modified mice Proteases and Cancer: Methods and Protocols (Methods in Molecular Biology. Springer-Nature. 1731, pp.179-192.

C.3. Research projects and contracts

1 **Project**. Control de la progresión tumoral y su respuesta inmune mediante el remodelamiento de la matriz extracelular: integración para una medicina de precisión. Ministerio de Ciencia e Innovación. Universidades. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/07/2020-30/06/2024.

2 **Project**. Estudio del microentorno extracelular en melanoma: en busca de nuevas herramientas para una medicina personalizada. Consejería de Salud. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/01/2019-31/12/2023.

3 **Project**. En búsqueda de herramientas para combatir la resistencia a terapia de la leucemia linfoblástica aguda B infantial: Estudios en torno al proteoglicano NG2 como diana innovadora.. Consejería de Salud. JC Rodríguez-Manzaneque. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 29/10/2021-28/10/2023. 123.750 €.

4 **Project**. Papel modulador de la proteasa extracelular ADAMTS1 en melanoma. Instituto de Salud Carlos III. Juan Carlos Rodríguez-Manzaneque Escribano. (FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD). 01/01/2017-31/12/2019.